Navigation Links
Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
Date:2/20/2008

EATONTOWN, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that total revenue for the year ending December 31, 2007 increased 5% to $104.3 million compared to $99.2 million for the year ended December 31, 2006. Revenue from "core" product lines, DBM and Hybrid/Synthetic products, was $67.6 million for full year 2007, an increase of 15% over core product revenue of $58.8 million in the prior year. Gross margin improved to 51.5% for the year ended December 31, 2007 compared to 48.2% in the same period in 2006.

Diluted earnings per share for the year ended December 31, 2007 was $.15 on net income of $2.6 million as compared to diluted earnings per share of $.11 for full year 2006 on net income of $1.9 million.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "It was a tremendous achievement and an important milestone in Osteotech's history to exceed $100 million in revenue. The world-wide Osteotech family contributed to this success and each member of the Osteotech team is proud of this accomplishment."

Mr. Owusu-Akyaw continued, "Our key financial metrics continue to demonstrate disciplined execution of our business plan. Our core products continue to grow while gross margin and profitability continue to improve. Our cash flow is strong and will allow us to support future growth. Our new product pipeline is solid, which we expect will increase our product offerings and is expected to be the major contributor to our growth."

Mr. Owusu-Akyaw concluded, "Just as Osteotech's pioneering tissue processing technology advanced the industry in the 1990's, Osteotech is developin
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Osteotech Announces Fourth Quarter and Full Year Earnings Release and Conference Call Schedule
2. Osteotech to Present at Sidoti Conference in San Francisco
3. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
4. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
6. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
7. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
10. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
11. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Quincy Bioscience, ... and development of calcium-binding proteins to support healthy ... safety assessment study of apoaequorin in ... published for the British Industrial Biological Research Association. ... to investigate potential adverse effects, if any, of ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... May 23, 2013 VG Energy, an ... with DAK Renewable Research to conduct field trials ... VG Energy is a majority owned subsidiary of ... VG Energy,s exclusively licensed compound LipidMax selectively ... yield in plants, possessing a wide variety of ...
Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3
... Gen-Probe Incorporated (NASDAQ: GPRO ) today ... revenues in the quarter grew 16%, to a new record ... 18%, to a new high of $0.72. "Gen-Probe ... fourth quarter while clinical diagnostics revenues continued their solid growth," ...
... Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer ... prescription medications, announced today that the company plans to ... beginning of the forthcoming month of March 2012 ... 1 Technologies is authorized to repurchase up to 10 ...
... New York, February 14, 2012 ... Oxygen Concentrator Market Shares, Strategies, and Forecasts, Worldwide, 2012 ... that it has a new study on Oxygen Concentrator ... has 524 pages, 191 tables and figures. , ,Reimbursement ...
Cached Biology Technology:Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 3Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 4Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 5Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 6Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 7Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 8Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 9Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 10Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 11Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 12Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 13Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 14Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 15Medisafe 1 Technologies to Start the $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share 2ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018 2ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018 3ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018 4ResearchMoz: Oxygen Concentrator Market Shares, Strategies and Forecasts, Worldwide, 2012 to 2018 5
(Date:5/23/2013)... the world,s most popular fruit, can be made both ... GM varieties. , "Working with GM tomatoes that ... of a specific compound, allows us to pinpoint exactly ... Martin from the John Innes Centre. , The research ... health and shelf life characteristics because even higher levels ...
(Date:5/23/2013)... than 13,000 ships per year, carrying more than 284 million ... roughly $1.8 billion dollars in toll fees for the Panama ... 55 million gallons of water are used from Gatun Lake, ... million people living in the isthmus. , However, the ... 20 percent of the ships at sea, has demanded change. ...
(Date:5/23/2013)... By discovering the new mechanism by which estrogen suppresses ... revealed a potential new approach toward treating certain liver ... and colleagues believe they are changing long-held views in ... issue of the journal Science Signaling . , ... years has been that only receptors located in the ...
Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2
... forest products industry has been growing rapidly since ... U.S. economy annually. Examples of nontimber forest products ... medicinal and herbal products, and specialty floral and ... U.S.-grown herbs used to satisfy increasing consumer demand ...
... with her studies challenging a popular theory that an ... evidence asserting her position. Gerta Keller, whose studies ... States, Mexico and India have led her to conclude ... likely culprits in the demise of the Earth,s giant ...
... & Life Sciences Division (DBIO) of the Special Libraries ... of biology and medicine over the last 100 years ... among them. In the poll, 686 DBIO members ... "Journals of Land Invertebrates" category. Annals celebrated its 100th ...
Cached Biology News:Decreasing deer damage 2Decreasing deer damage 3Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 2Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 3Princeton geoscientist offers new evidence that meteorite did not wipe out dinosaurs 4'Annals of the ESA' selected as one of 100 most influential journals 2
... bioassays for interferons are cytopathic effect inhibition assays, ... Sample types include; tissue culture supernatents; serum from ... assays, one unit is defined as the quantity ... cytopathic effect of viral infection by 50%. ...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
Request Info...
Biology Products: